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Abstract: Microalgae represent a source of bio-active compounds such as carotenoids with potent
anti-inflammatory and antioxidant properties. We aimed to investigate the effects of fucoxanthin
(FX) in both in vitro and in vivo skin models. Firstly, its anti-inflammatory activity was evaluated in
LPS-stimulated THP-1 macrophages and TNF-α-stimulated HaCaT keratinocytes, and its antioxidant
activity in UVB-irradiated HaCaT cells. Next, in vitro and ex vivo permeation studies were developed
to determine the most suitable formulation for in vivo FX topical application. Then, we evaluated
the effects of a FX-containing cream on TPA-induced epidermal hyperplasia in mice, as well as on
UVB-induced acute erythema in hairless mice. Our results confirmed the in vitro reduction of TNF-α,
IL-6, ROS and LDH production. Since the permeation results showed that cream was the most
favourable vehicle, FX-cream was elaborated. This formulation effectively ameliorated TPA-induced
hyperplasia, by reducing skin edema, epidermal thickness, MPO activity and COX-2 expression.
Moreover, FX-cream reduced UVB-induced erythema through down-regulation of COX-2 and iNOS
as well as up-regulation of HO-1 protein via Nrf-2 pathway. In conclusion, FX, administered in a
topical formulation, could be a novel natural adjuvant for preventing exacerbations associated with
skin inflammatory pathologies as well as protecting skin against UV radiation.
Keywords: fucoxanthin; inflammation; epidermal hyperplasia; UVB; photoprotection
1. Introduction
Skin is the organ that acts as main defence against external environment factors, protecting
the organism from harmful substances, mechanical damage, pathological invasion and radiations.
Nonetheless, the normal structure and functionality could be altered by external factors such as toxic
compounds or ultraviolet (UV) radiation, or by internal factors including genetic predisposition,
immune and hormone disorders, or stress. The result of these skin perturbations could trigger an
inflammatory process, an oxidative stress status, an unbalanced epidermal homeostasis, or a limited
immune response, among others [1].
In this respect, inflammatory skin diseases such as psoriasis, atopic dermatitis or rosacea have
harsh clinical implications because of their chronic curse and lead to develop comorbidities that make
difficult their treatment and have a remarkable impact on the quality-of-life of patients [2]. Nowadays,
UV skin exposure to treat these inflammatory conditions is recommended due to its beneficial
effects. In this line, UV radiation achieves long remission periods in psoriasis through activation
of immunosuppressive pathways and keratinocyte apoptosis [3]. On the other hand, detrimental
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effects of UVB radiation exposure (280–315 nm) have been extensively reported: it promotes a strong
acute inflammatory response characterized by activation and recruitment of innate immune cells
such as neutrophils and macrophages to the epidermis and dermis. In addition, UVB radiation is the
main source of reactive oxygen species (ROS) production, which increases the inflammatory response,
causing DNA oxidative damage in keratinocytes [4]. For this reason, new approaches to modulate
the skin inflammation and protect against UV radiation are necessary to supplement the existing skin
anti-inflammatory therapies.
Currently, marine resources are recognized for their variety of biologically active substances [5],
which are becoming important ingredients in skin care products due to their potent anti-inflammatory
and antioxidant actions as well as the safety and low risk in their administration [6]. In this sense,
carotenoids have shown antioxidant, anti-inflammatory or anti-carcinogenic properties in different
skin inflammatory models [7]. Fucoxanthin (FX) is an orange carotenoid present in brown seaweeds,
diatoms and microalgae [8], whose antioxidant activity has been well demonstrated in previous
studies [9,10]. Particularly, FX has shown to enhance AKT/ nuclear factor (erythroid-derived 2)-like 2
(Nrf2)/glutathione (GSH)-dependent antioxidant response in keratinocytes [11]. Moreover, this
carotenoid reduces wrinkle formation and epidermal hypertrophy in mice [12] and suppresses
melanogenesis and prostaglandin synthesis [13]. In addition, FX has been proposed as a photoprotective
compound by stimulating restoration of the skin barrier in UVA-induced sunburn [14]. However,
the protective effect of a FX-containing topical formulation has not been described yet on a skin
inflammatory model. The possibility to administer FX topically has been subjected to several
drawbacks because of its molecular weight and lipophilicity. As it is known, the compound must
diffuse across stratum corneum and tight junctions to achieve effective permeation. In this sense, topical
dosage forms such as creams, ointments, lotions and gels are commonly used for enhancing the
cutaneous penetration. Thus, their composition will affect the drug permeation [15]. Concerning
FX, several preparations have been studied with this aim [16,17]; in all of them, the evaluation of
cutaneous penetration is a useful approach to predict the safety and efficacy of formulations [18].
To date, previous papers have developed topical experiments in mice applying acetone-dissolved
compounds on skin [12,19]. With the aim of solving the irritant effect of acetone for its use in humans,
a previous study from our group recently evaluated a glycolipid fraction-containing cream formulation
on the murine 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced epidermal hyperplasia model.
Our findings reported an anti-inflammatory effect of this formulation with no signs of toxicity [20].
In the present study, we evaluated the anti-inflammatory and antioxidant properties of
FX-containing cream in both in vitro and in vivo models in order to justify its use as adjuvant in
inflammatory skin pathologies in which sun exposition is recommended. Firstly, we carried out two
in vitro models to elucidate its anti-inflammatory and antioxidant activity. Then, FX was dissolved
in absolute ethanol to further be incorporated into several common topical formulations (ointment,
cream or hydrophilic gel). Once a topical formulation was selected, we finally aimed to study its effect
on the TPA-induced hyperplasia model in mice, which mimics psoriatic parameters in dorsal murine
skin, and on the UVB-induced erythema model in hairless mice, which reproduces the consequences
expected in humans receiving acute UVB radiation.
2. Results
2.1. Effect of FX on Cell Viability
The effect of FX on THP-1 macrophages and HaCaT cells viability was measured by using
the sulforhodamine B (SRB) assay. Results from cytotoxicity study showed that none of the tested
concentrations affected cell viability. The inhibitory concentration 50 (IC50) (half maximal inhibitory
concentration) was above 100 µM at 24 h after treatment (Table S1).
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2.2. Effects of FX on TNF-α Production in LPS-Stimulated THP-1 Macrophages and IL-6 and IL-8 Production
in TNF-α-Stimulated HaCaT Human Keratinocytes
Non-cytotoxic concentrations of FX were used to determinate its effect on pro-inflammatory
cytokines in both THP-1 macrophages and human keratinocytes. As shown in Figure 1, all concentrations
tested significantly reduced the production of inflammatory cytokines in both cell models. Interestingly,
the pre-treatment with the carotenoid at 50 µM showed a significant reduction of tumor necrosis factor
alpha (TNF-α) production in lipopolysaccharide (LPS)-stimulated THP-1 macrophages, reaching
similar values to dexamethasone (Dex) (p < 0.001) (Figure 1A). In relation to interleukin (IL)-6 and IL-8
production in HaCaT keratinocytes, similar results were exhibited in cells pretreated with the highest
dose of FX (p < 0.001) (Figure 1B,C).
1 
 
 
Figure 1. Effects of fucoxanthin (FX) on pro-inflammatory cytokines production in THP-1
macrophages and HaCaT keratinocytes. (A) Tumor necrosis factor alpha (TNF-α) in lipopolysaccharide
(LPS)-stimulated THP-1 macrophages. (B) Interleukin (IL)-6 and (C) IL-8 in TNF-α-stimulated HaCaT
keratinocytes. Cells were treated with FX (10, 30 and 50 µM) for 1 h, and then stimulated with LPS
(1 µg/mL) in THP-1 macrophages or TNF-α (10 ng/mL) in HaCaT cells for 24 h. Dexamethasone
(Dex) was used as positive reference compound at 1 µM. Production of cytokines in supernatant was
measured by ELISA assay. Results are representative of six independent experiments. Values are means
with standard errors represented by vertical bars. The mean value was significantly different compared
with the control group (*** p < 0.001; Student t test). Mean value was significantly different compared
with the LPS or TNF-α group (+ p < 0.05, ++ p < 0.01, +++ p < 0.001; one-way ANOVA followed by
Bonferroni’s Multiple Comparison test).
2.3. In Vitro Permeation Studies of BC from Different Topical Formulations
The objective of this study was to evaluate the in vitro permeation through artificial membranes of
β-carotene (BC) from different topical formulations. BC was selected because of its structural similarity
with FX. The formulations tested were: ethanolic solution as control, hydrogel, cream and ointment.
BC was detected in the receiver medium in a time-dependent manner and profiles of cumulative
amount of drug permeated have been obtained (Figure 2).
The permeation profiles showed the cream as the most favourable vehicle as penetration enhancer.
When compared with the ethanolic control solution, a high percentage of BC permeated was obtained
at a flux very similar to the control solution, as reported in Table 1. However, the ointment and hydrogel
preparations made it difficult the pass through the membrane, probably due to their lipophilic and
hydrophilic nature, respectively. This was visualized in terms of lower permeation percentages and flux
rates. Hydrophilic cream provided the highest release of BC in comparison with lipophilic ointment or
hydrogels, as previously reported for flavonoids [21]. Therefore, the hydrophilic cream (oil-in-water
(OW) emulsion base) was chosen for incorporating FX and Dex for further studies. As these emulsions
have hydrophilic external phase, they are miscible with water and skin secretions, thus they are not
occlusive and are easily removed from skin.
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Figure 2. Permeation profiles. (A) In vitro permeation profile of β-Carotene (BC) from different topical
formulations: cream, ointment and gel. BC dissolved in absolute ethanol was used as control solution.
Artificial membranes impregnated with N-dodecanol mimicked the skin barrier. Absolute ethanol was
used as release medium. (B) In vitro permeation profiles of fucoxanthin (FX) and dexamethasone (Dex)
from cream formulation. FX dissolved in absolute ethanol was used as control solution. Dex-loaded
cream was used as positive control. The experimental procedure was similar to that for BC. The
percentages of drug release were obtained from the amount of drug that reached the receiver medium
with time. These values are expressed in percentage, where 100% corresponds to the theoretical amount
of drug added to the formulation. Data are represented as the mean ± standard error (n = 3).
Table 1. Total percentage permeated across artificial lipophilic membrane of β-carotene (BC) from
different topical formulations, and flux rate (Jss) (µg/cm2·min) calculated from the slope of amount
permeated per area versus time.
Formulation % Permeation (180 min) Flux (Jss) (µg/cm2·min) r2
Cream 68.38 0.1159 0.9795
Ointment 47.31 0.0548 0.9704
Hydrogel 25 0.0383 0.9403
Control 100 0.1350 0.9862
2.4. Ex Vivo Permeation Studies of FX-Containing Cream
Once the cream was selected as the vehicle for drug formulation, FX-loaded cream was prepared
following the same methodology that for BC. In addition, Dex-loaded cream was formulated as
positive control for the in vivo assay. The permeation profiles of FX contained in the hydrophilic cream
were evaluated with the aim of analyzing the permeation behavior in the mice skin compared to an
ethanolic control solution and Dex-cream.
Results showed a clear improvement of FX permeation with time (Figure 2). As evidenced from
the area under the drug permeation curve (AUC) calculated (48,610, 19,914 and 8671%/h for FX-cream,
FX control and Dex-cream, respectively), the cream vehicle offered a higher amount of FX permeated
with time, whereas the control solution of this molecule showed a lower percentage. Although the
ethanol acts as permeation enhancer, the cream composition, rich in surfactants, made the formulation
improve the amount of FX to cross the membrane. Surprisingly, the permeation profile of Dex-cream
showed 15%, approximately, of drug permeation. This lack of diffusion across the membrane could be
attributed to a lower partition coefficient than FX (1.83 vs. 14.76). Dex has a lower molecular weight
than FX, but the lipophilic nature of the carotenoid makes it a better candidate to interact with the
surfactant components of the cream, which aids the solubilized molecule to reach the receiver medium.
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2.5. Topical Application of FX-Containing Cream Decreases Skin Inflammation and Hyperplasia on the Murine
TPA-Induced Model
To analyze whether topical pre-treatment with FX could reduce the in vivo inflammation, we
studied this carotenoid on the murine TPA-induced epidermal hyperplasia model. Topical pre-treatment
with FX-cream (100 mg per site containing 200 µg of FX) and Dex (100 mg per site containing 200 µg of
Dex) was administered from 2 days before TPA-induced hyperplasia and 1 h after each TPA application
(2 nmol per zone for three consecutive days). Then, 24 h after the last application of TPA, mice were
sacrificed and skin biopsies were removed and weighted. Mice treated with TPA or TPA-cream resulted
in the development of macroscopic lesions as peeling (Figure 3A), confirmed by an increase of weight of
the 1 cm2 punch biopsies of dorsal skin, in comparison with sham group (p < 0.001), with no significant
differences between both groups (Figure 3B). This comparison led us to confirm that cream did not
interfere in TPA action in our experiment. As expected, pre-treatment with the reference compound
Dex significantly reduced the skin punch weight (p < 0.001). Similarly, mice treated with FX-cream
showed a significant attenuation of skin edema when compared with TPA-cream group (p < 0.001)
(Figure 3B). We next analyzed the skin homogenates to evaluate myeloperoxidase (MPO) activity as a
neutrophil infiltration parameter with important relevance in hyperplasia model (Figure 3E). Our results
confirm that this marker significantly increased after TPA application in comparison with sham group
(p < 0.01). Dex application markedly diminished MPO activity in relation to TPA-cream group (p < 0.01).
In a similar way, this parameter was reduced by FX-cream (p < 0.05) (Figure 3E). These results were
confirmed with histological analysis of hematoxylin and eosin (H&E)-stained skin lesions in mice
(Figure 3C), which showed that TPA administration produced a massive neutrophilic infiltration and an
epidermal hyperplasia, because of uncontrolled and abnormal keratinocyte production. This effect was
evidenced by a marked increase of epidermal thickness in this group (p < 0.001). Animals pre-treated
with Dex and FX-cream evidenced a significant improvement in epidermal hyperplasia in relation to
TPA-cream group (p < 0.001, and p < 0.01, respectively) (Figure 3C,D).
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12-O-tetradecanoylphorbol-13-acetate (TPA) in mice (n = 10 mice/group). FX-cream formulation
(100 mg per site at 200 µg), dexamethasone (Dex, 100 mg per site at 200 µg) or vehicle (cream with 0.2%
ethanol) were topically administered as described in Material and methods. (A) Macroscopic mice back
appearance at the end of experiment. (B) Skin edema as punch biopsy. (C) Histological appearance of
mouse dorsal skin after hematoxylin/eosin (H&E)-staining; Bar = 10 mm. Original magnification 100×
(D) Epidermal thickness assessme t in H&E-stained skin slides. (E) Myeloperoxidase (MPO) activity.
Values are means with standard errors represented by vertical bars. The mean value was significantly
different compared with the sham group (** p < 0.01, *** p < 0.001; Student t test). Th mean value w s
significantly different compared with TPA-cream group (+ p < 0.05, ++ p < 0.01, +++ p < .001; one-way
ANOVA followed by Bonferroni’s Multiple Comparison t st).
To support the beneficial effects of FX on skin inflammation and explore its possible mechanism
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Figure 4. Topical application of fucoxanthin (FX) reduced 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced epidermal cyclooxygenase-2 (COX-2) expression in mice. (A) Representative
photographs of epidermal COX-2 distribution by immunohistochemical detection; Bar = 12.7 mm.
Original magnification 200×. (B) Percentage of COX-2 positivity in epidermal layer was assessed by
counting the number of COX-2 positive cells vs. total cells from 10 equal sections of immunostained
dorsal skin per animal (n = 3). Values are means with standard errors represented by vertical bars.
The mean value was significantly different compared with the sham group (*** p < 0.001; Student t test).
The mean value was significantly different compared with TPA-cream group (+++ p < 0.001; one-way
ANOVA followed by Bonferroni’s Multiple Comparison test).
2.6. FX Protects Human HaCaT Keratinocytes against UVB-Caused Damage
To examine the protective effect of FX in irradiated HaCaT cells, we evaluated cell viability by
lactate dehydrogenase (LDH) enzyme activity, ROS levels and IL-6 production after UVB exposure.
As expected, UVB irradiation significantly increased LDH activity, ROS content and IL-6 production in
HaCaT keratinocytes compared to unirradiated control (p < 0.001) (Figure 5A–C). Pre-treatment of
cells with FX 1 h prior to UVB exposure significantly decreased UVB-induced mortality, preserving
cell membrane integrity in a dose-dependent manner at all concentrations used (10, 30 and 50 µM,
p < 0.05, p < 0.01, p < 0.001, respectively) (Figure 5A). We next evaluated intracellular ROS levels
in UVB-irradiated cells based on the dichlorofluorescein diacetate (DCF-DA) assay (Figure 5B).
FX markedly reduced ROS levels by 23, 31 and 32% at the concentration of 10, 30 and 50 µM,
respectively (p < 0.01, p < 0.001, p < 0.001) (Figure 5B).
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Figure 5. Protective effect of fucoxanthin (FX) on UVB-induced damage in HaCaT cells. Keratinocytes
were preincubated with FX (10, 30 and 50 µM) for 1 h prior to UVB (50 mJ/cm2) exposure. (A) After
24 h, cell viability was assessed by using lactate dehydrogenase (LDH) assay. (B) Intracellular reactive
oxygen species (ROS) generation was measured 30 min after UVB irradiation by relative fluorescence
intensity using dichlorofluorescin-diacetate (DCF-DA) assay. (C) Interleukin (IL)-6 production was
evaluated by ELISA assay, 24 after UVB exposure. Cell viability and ROS production are expressed
as percentage respect to UVB-irradiated cells and IL-6 levels as pg/mL. Results are representative of
four independent experiments. Values are means with standard errors represented by vertical bars.
The mean value was significantly different compared with the control group (*** p < 0.001; Student
t test). The mean value was significantly different compared with UVB group (+ p < 0.05, ++ p < 0.01,
+++ p < 0.001; one-way ANOVA followed by Bonferroni’s Multiple Comparison test).
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It is known that UVB exposure induces abnormally augmented cytokine production from
keratinocytes, leading to inflammatory skin disorders. To evaluate the effect of FX on IL-6 production,
HaCaT cells were pre-treated for 1 h with this carotenoid, and then were exposed to UVB. Pre-treatment
with FX at the concentrations tested of 10, 30 and 50 µM substantially inhibited this cytokine levels by
23, 31 and 59%, respectively (p < 0.001) (Figure 5C).
2.7. Topical Application of FX-Containing Cream Protects against UVB-Induced Skin Erythema in SKH-1
Hairless Mice
The possible photoprotective effect of the topical pre-treatment with FX-cream in hairless mice
was assayed using an acute proinflammatory UVB dose (360 mJ/cm2) [22]. BC-cream was employed as
reference compound due to its antioxidant and photoprotective activity [23]. Animals were examined
with a dermatoscope for five days, evaluating UVB-induced skin alterations. As shown in Figure 6A,
a single acute UVB exposure accelerated skin damage, showing typical symptoms such as peeling,
loss of moisture, reduction of elasticity and increase of melanin production in comparison with sham
controls (Figure 6A–D). The progressive evaluation of mice showed that pre-treatment with FX-cream
increased the skin moisture (Figure 6B) and elasticity (Figure 6C) and decreased the production of
melanin (Figure 6D), with similar values to BC-cream. In order to confirm the protective profile of FX,
48 h after UVB irradiation, the mice were sacrificed and dorsal skin was examined. Our data reflected
significant increases of skin edema and MPO activity in UVB-irradiated group when compared with
sham (p < 0.001). The reference group, BC-cream, showed pronounced lower levels of these parameters
when compared to UVB-irradiated group (p < 0.001, p < 0.05, respectively) (Figure 6E,F). Similar
results were found after pre-treatment with FX-cream (Figure 6E,F). These findings were confirmed
by histological study by using H&E staining. Histologically, a significant increase in superficial skin
layer thickness due to unregulated keratinocytes proliferation was detected in UVB-irradiated animals
in comparison to sham (p < 0.001) (Figure 6G,H). FX-cream treatment was as effective as topical
application of BC-cream; our data revealed a decrease in keratinocytes proliferation when compared
to UVB-irradiated group, evidenced by a significant reduction of epidermal thickness (p < 0.001)
(Figure 6G,H).
To further explore the possible mechanisms of action of FX, we examined the expression levels
of different inflammatory and antioxidant proteins in dorsal skin samples. Exposure of skin to
UVB induced a significant increase in the pro-inflammatory enzymes iNOS (p < 0.001) and COX-2
(p < 0.001) expression (Figure 7B,C). Neither of these proteins changed significantly in animals
treated with the reference compound BC-cream. However, pre-treatment with FX-cream resulted in a
significant downregulation of COX-2 expression levels in irradiated mice (p < 0.05) in comparison with
UVB-irradiated animals. As regards the iNOS protein, although its expression tended to decrease in
FX-cream-treated animals, no significant differences were observed in relation to UVB-treated mice.
UVB exposure significantly down-regulated the expression of Nrf-2 protein (p < 0.05). BC-cream
application induced a marked increase in Nrf2 levels (p < 0.001) accompanied with a rise of its target
gene heme oxygenase-1 (HO-1) (p < 0.05). In a similar way, FX-cream significantly increased the
expression of these antioxidant proteins in UVB-exposed skin (p < 0.01 and p < 0.05, respectively)
(Figure 7D,E).
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Figure 6. Fucoxanthin (FX) has photoprotective effects in UVB-induced erythema model in hairless mice
(n = 8 mice/group). Mice received a single UVB radiation dose of 360 mJ/cm2. FX-cream formulation
(FX-cream, 100 mg per site at 200 µg), β-carotene-cre m (BC-cream, 100 mg per site at 200 µg) or
vehicle (cream with 0.2% ethanol) were topically administered as describe in Material and methods.
(A) Macroscopic mice back appearance at the end of experim nt. (B) Skin moisture, (C) skin elasticity
and (D) melanin index were evaluated during all experiment. (a.u), arbitrary nits. (E) Determination
of skin edema as punch biopsy weight. (F) Myelop roxidase ( PO) activity. (G) Measurement of the
epidermal thickness in hematoxy in/eosin (H&E)-stained skin slides. (H) Photomicrographs of mouse
dorsal sk n after H&E-staining; Bar = 10 mm. Original ma nification 100×. Values are means with
standard errors represe ted by vertical bars. The mean value was significantly different compared with
the sham group (*** p < 0.001; Student t test). The mean value was significantly different compared with
UVB-exposed group (+ p < 0.05, +++ p < 0.001; one-way ANOVA followed by Bonferroni’s Multiple
Comparison test).
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Figure 7. Anti-inflammatory and a tioxidant effects of fucoxanthin (FX) in UVB-induce erythema
model in hairless mice (n = 8 mice/group). Mice received a single UVB radiation dose of 360 mJ/c 2.
FX-cream formulation (100 mg per site at 200 µg), β-carotene-cream (BC-cream, 100 mg per site at
200 µg) or vehicle (crea ith 0.2 ethanol) ere topically ad inistered as described in aterial
and ethods. (A) Representative Western blot images of different skin proteins. Densitometric
analysis of (B) inducible nitric oxide synthase (i OS), (C) cyclooxygenase-2 (COX-2), (D) nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) and (E) heme oxygenase-1 (HO-1) proteins. Data were studied
following normalization to the control (housekeeping gene, β-actin). Values are means with standard
errors represented by vertical bars. The mean value was significantly different compared with the sham
group (* p < 0.05, *** p < 0.001; Student t test). The mean value was significantly different compared with
UVB-exposed group (+ p < 0.05, ++ p < 0.01, +++ p < 0.001 one-way ANOVA followed by Bonferroni’s
Multiple Comparison test).
3. Discussion
FX has formerly demonstrated in vitro and in vivo anti-inflammatory and antioxidant
activities [11,14,24]. Nevertheless, the use of topical formulations such as cream/emulsion containing
this carotenoid to prevent exacerbations related with skin inflammatory pathologies and provide
a photoprotective effect has not been previously evidenced. Treatment of the skin with these
topical formulations is a rational approach since avoids gastrointestinal degradation and preserves
bioavailability [25].
Firstly, in the present study, we confirmed the in vitro anti-inflammatory activity of FX through
decrease in TNF-α production in LPS-stimulated macrophages and reduction of IL-6 and IL-8 levels
in TNF-α-stimulated HaCaT keratinocytes. These results led us to evaluate the possible preventive
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effects of this carotenoid on two in vivo acute skin inflammatory models: a hyperplasia model induced
by multiple applications of TPA and an erythema model induced by a single UVB challenge.
Drug delivery across the skin remains as an important challenge in the development of drug
delivery systems. This is mainly attributed to the highly organized intercellular lipids and poor
permeability of stratum corneum [26]. It is also well-known that lipophilic molecules move across the
barrier by a transcellular mechanism whereas hydrophilic agents are likely to follow a paracellular
pathway to cross the skin. FX is lipophilic with a high partition coefficient (log P 6.83–7.54). To date,
some studies with FX have been carried out by dissolving FX in ethanol for applying the drug
dissolved onto the skin [12]. However, this solvent is known to produce dryness effect in the skin.
To improve FX topical application, various hydrophilic and lipid-based formulations have been
developed, firstly using BC as model drug because of its structural similarity to FX [27]. In this
sense, new approaches are desirable in order to avoid the use of uncomfortable formulations such
as paraffin [13]. In order to have a prediction of the in vivo permeation behaviour of the drug
and to avoid the expensive cost of the use of animals or human skin, alternative artificial skin
diffusion apparatus was used for conducting in vitro permeation studies. As regards the formulations
tested (cream, ointment and hydrogel), it was found that lipid-based formulations improved most
efficiently the diffusion of BC through the permeation membrane in a Franz diffusion cell. In contrast,
water-based formulations, such as Carbopol gel, exhibited poor penetration. The composition of cream,
which was highly charged in surfactants, makes it to act as a permeation enhancer that changes the
atmosphere of the lipids to encourage the diffusion of lipid molecules (BC or FX) and/or influence
their solubility [28]. The blend of agents with polar and non-polar properties, which probably mimic
the complex lipid/polar nature of the stratum corneum, makes the cream thermodynamically similar
to the stratum corneum, enabling the permeation of BC through the skin. Other authors incorporated
surfactant-like molecules (D-α-tocopheryl polyethylene glycol 1000 succinate) into the formulations
for synergistically acting with ethanol as solubilizing agents of griseofulvin [29]. This is the reason
why formulations too occlusive and lipophilic (ointment) make difficult the permeation process of
poorly water-soluble compounds. On the contrary, concerning the highly hydrophilic formulations
(gel), it is known that water can generate a resistant boundary at the donor-skin interface (impregnated
in our artificial membranes with dodecanol) and may prolong or delay the permeation of poorly
water-soluble molecules such as BC.
Once we selected the cream as a vehicle for our studies, we proceeded to elucidate the FX
behaviour in terms of permeation kinetics through a comparative study with control solution and
Dex-cream. This carotenoid has been previously formulated in O/W formulations by other authors [16].
Our results showed that, under the experimental conditions used, FX-cream has a higher permeability
though artificial membrane than the other formulations (control solution FX and Dex-cream). Other
authors reported that the differences in penetration might be associated with the variation in the
lipophilicity of the tested compounds [30], as obtained in this case. Although Dex has a lower molecular
weight than FX, which might favour the diffusion across the membrane, its low lipophilicity (log P 1.83)
compared to FX, makes more difficult this passage, showing permeation profiles more reduced [26].
The efficacy of FX-loaded O/W emulsions has been demonstrated as anti-obesity formulations
being prepared by using medium chain triglyceride as an oil phase and l-α-phosphatidylcholine
as an emulsifier [17,31]. This heterogeneous disperse system has been also used for incorporating
other antioxidant molecules such as green tea polyphenols with the aim of preventing UVB-induced
oxidation of lipids in mouse skin [21]. Thus, hydrophilic cream may serve as an optimal delivery
system for FX use in animal models.
TPA is an activator of protein kinase C isoenzymes and a well-known inducer of inflammatory
response in murine skin rising expression of the inflammation mediators [32]. TPA-induced hyperplasia
model in dorsal murine skin reproduces typical manifestations of inflammatory skin pathologies as
psoriasis. In this regards, TPA administration causes macroscopic lesions such as erythema or peeling,
as well as increment of epidermis thickness by hyperproliferation and aberrant differentiation of
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keratinocytes or leukocytes infiltration into the dermis and consequent cytokines and chemokines
production [33]. The pre-treatment with FX-cream ameliorated skin hyperplasia reducing MPO
activity, as indicatory of leucocyte infiltration, and skin edema. These results were related with the
improvement of histological damage by reducing epidermal thickness and neutrophil infiltration,
getting similar levels to those of the reference corticosteroid Dex. The relation between epidermal
differentiation and COX-2 expression has been strongly reported, as well as their connection with
the pathogenesis of psoriasis [34]. In this sense, repeated applications of TPA in dorsal murine skin
induce inflammation symptoms that are accompanied by COX-2 epidermal overexpression in relation
with healthy group [35]. Our data evidenced a reduced COX-2 expression in mice treated with FX,
presenting lower levels than those in Dex group. These findings, at least partly, suggest that suppression
of COX-2 expression may be involved in the preventive effect of this carotenoid on TPA-induced
epidermal hyperplasia. Our results are in agreement with previous in vitro studies that showed the
capacity of FX to modulate inflammatory response through inhibition of COX-2 and iNOS expression
and the consequent decrease of NO and prostaglandin E2 levels [24,36]. The molecular mechanisms
underlying the anti-inflammatory properties of FX may be associated with the suppression of nuclear
factor-kappaB and mitogen-activated protein kinase pathways, similar to those previously reported
for Dex in skin inflammatory pathologies [37]. More recently, FX has shown to downregulate COX-2
levels in a murine model of high-fat-diet-induced obesity [38]. It is well known that inflammatory
pathologies as psoriasis require long-term topical corticosteroids therapy, which is associated with
both topical and systemic adverse effects. Moreover, the chronic use of these compounds may increase
tendency to “steroid addiction syndrome”, which forces to change the corticoid and select one more
potent [39]. For these reasons, the use of a well-tolerated immune-modulatory topical formulation
containing FX could offer a safer alternative to continued use of corticoids for the treatment of skin
inflammatory disorders.
Additionally, it is worth highlighting that since these pathologies benefit from therapeutic sun
exposition, it is very important to assure the photoprotection of exposed skin. Sunscreens are used
to prevent the deleterious effects of UVB due to this radiation remains as an important risk factor
to develop skin lesions [40]. In this sense, further therapeutic strategies targeting UVB-induced
inflammation and oxidative stress are necessary. Thus, our next objective was to examine the
photoprotective effects of FX in an UVB-induced cell damage model in HaCaT keratinocytes, as well
as on an UVB-induced erythema model in hairless mice in order to complete the functional activity
study of this compound as adjuvant treatment in skin inflammatory disorders. It is well known that
UVB irradiation induces cell cytotoxicity through loss of cellular membrane integrity, which leads
to liberation of LDH enzyme from cytosol to the culture medium [41]. Moreover, UVB radiation
causes increased ROS production and DNA damage, as well as a strong inflammatory response,
characterized by the production of inflammatory cytokines, such as IL-6, which leads to premature
skin aging and carcinomas [42]. Recently, it has been demonstrated that the antioxidative role of
FX in HaCaT keratinocytes is related to DNA protection against oxidative stress and the prevention
of apoptosis [43,44]. According with these results, we have shown that pre-treatment of HaCaT
keratinocytes with FX significantly attenuated UVB-induced damage by increasing cell viability and
inhibiting ROS and IL-6 levels.
In relation to in vivo alterations, acute UVB radiation promotes erythema, edema and loss of skin
moisture and elasticity, as well as increases melanin production, which is involved in melanogenesis.
Recently, several studies have revealed the photoprotective effects of FX in UVB-irradiated mice by
reducing melanogenesis parameters [13] and in UVA-induced sunburn by promotion of skin barrier
formation [14]. In addition, this carotenoid prevented skin photoaging in hairless mice through its
antiangiogenic and antioxidant effects [12]. Herein, we report that the topical pre-treatment with
FX-cream formulation ameliorated erythema induced by UVB as well as edema and MPO activity,
which are important inflammation and neutrophil recruitment parameters. Overexpression of COX-2
is highly related to some carcinomas including skin cancer [45]. In this regard, and in accordance to
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the above results from TPA model, we also reported the reduction of COX-2 expression by FX-cream
pre-treatment on UVB-exposed skin, effect not observed upon BC administration.
It has been reported that excessive ROS generation results in oxidative stress in skin cells and
plays a vital role in the initiation, promotion and progression of skin aging, carcinogenesis and many
inflammatory disorders [46]. In this respect, Nrf2 is a transcription factor that perceives variation
in cellular oxidative stress and promotes the transcription of antioxidant genes and detoxification
enzymes such as HO-1 to protect against UVB-induced oxidative damage [47,48]. An in vitro study
has elicited the antioxidant activity of FX by enhancing the Akt/Nrf2/GSH pathways in human
keratinocytes [11]. Moreover, FX has been recently shown to be able to activate Nrf2 signalling
pathway by inducing demethylation of CpG sites in Nrf2 [49]. In accordance with these results,
our data reported that FX and BC offer a similar protection against oxidative stress caused by UVB
exposure via increase of Nrf2 expression and its downstream target HO-1. However, in a previous
paper FX was confirmed to have higher antioxidative effects than BC, due to its more polar nature and
consequent placement in the cell membrane [50]. In the present study, although the two carotenoids
have shown to have similar antioxidant properties, FX provides additional benefits, exhibiting an
anti-inflammatory activity by downregulating COX-2 expression after UVB irradiation. These findings
propose this carotenoid as a natural approach for protecting skin against UV radiation and modulating
the inflammatory response associated.
4. Materials and Methods
4.1. Cell Culture
The THP-1 human monocytic leukemia cell line and HaCaT human keratinocytes were obtained
from the American Type Culture Collection (ATCC, Manassas, VA, USA). THP-1 cells were cultured in
RPMI 1640 medium (GIBCO, Grand Island, New York, NY, USA) containing 10% heat-inactivated fetal
bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin. HaCaT human keratinocytes
were maintained in high glucose Dulbecco’s modified Eagle’s medium (DMEM, GIBCO, Grand Island,
New York, NY, USA). Both cell lines were grown in a humidified atmosphere containing 5% CO2 at
37 ◦C [20].
4.2. Cell Viability Assay
SRB assay was used for determining the viability of THP-1 macrophages and HaCaT cells
upon exposure to FX (Sigma-Aldrich, St. Louis, MO, USA) [51]. Firstly, for differentiation into
macrophages, THP-1 cells were seeded into 96-well plates at 104 cells/well in presence of phorbol
12-myristate 13-acetate (PMA, Sigma-Aldrich, St. Louis, MO, USA) for a final concentration of 0.2 µM
for 72 h in 96-well plates and HaCaT cells were seeded into 96-well plates in the growth medium at
104 cells/well for 24 h to ensure the adherence. Both cellular types were incubated in a humidified
atmosphere of 5% CO2 at 37 ◦C. After that, cells were treated with FX at final concentrations range of
10–100 µM in DMSO 0.1% (v/v) and the cytotoxicity was measured after 24, 48 and 72 h of incubation.
The absorbance was determined at 492 nm in a microplate spectrophotometer (Sinergy HT, Biotek®,
Bad Friedrichshall, Germany).
4.3. Determination of TNF-α Production
THP-1 monocytes were differentiated into macrophages in 96-well plates (104 cells/well). Then,
cells were incubated for 1 h with FX (10, 30 and 50 µM). The positive reference compound used was
Dex (1 µM) (Sigma-Aldrich, St. Louis, MO, USA). Inflammatory response was induced by addition of
LPS (1 µg/mL) except for control group [52]. After 24 h, commercial enzyme-linked immunosorbent
assay (ELISA) kit (Diaclone GEN-PROBE, Besançon, France) was used to quantify TNF-α according to
the manufacturer’s protocol.
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4.4. Determination of IL-6 and IL-8 Production
HaCaT cells were seeded in 6-well plates (5 × 105 cells/well). After 24 h, cells were washed twice
(PBS, 4 ◦C) and medium containing FX (10, 30 and 50 µM) or Dex (1 µM) was added for 1 h, and then
cells were stimulated with TNF-α (10 ng/mL) except for control group. After 24 h, supernatant
fluids were collected and stored −80 ◦C until measurements [20]. Commercial enzyme-linked
immunosorbent assay (ELISA) kit (Diaclone GEN-PROBE, Besançon, France) was used to quantify
IL-6 and IL-8 according to the manufacturer’s protocol.
4.5. Preparation of Topical Formulations
Based on previous studies, topical formulations were performed following the methodology
detailed in Rodríguez-Luna et al. [20]. Thus, three different preparations were developed: hydrogel,
cream and ointment. Concerning the hydrogel, BC (Sigma-Aldrich, St. Louis, MO, USA) solution
in ethanol absolute (10 mg/mL) was gradually added to the polymer dispersion (1% w/v) under
magnetic stirring. The ointment was prepared using both the melt emulsification and stirring steps.
BC dissolved in ethanol (10 mg/mL) was added to the lipid mixture. Regarding cream, three different
preparations were made containing 2 mg/g of drug (BC, FX or Dex). In all of them, the drug was
dissolved in absolute ethanol (10 mg/mL) and added to the excipient cold mixture.
4.6. In Vitro Permeation Studies from Topical Formulations
In vitro drug permeation studies from the topical formulations were performed using a Franz
diffusion cell apparatus (SES-Gmgh Analyses system, Bechenheim, Germany), with 14.5 mL receptor
volume and 3.14 cm2 diffusion area. An appropriately conditioned cellulose nitrate membrane
(Tuffryn®; Pall Corporation, Port Washington, New York, NY, USA), impregnated with lauryl alcohol
(membrane weight increase 90–110%), was employed as artificial lipophilic membrane simulating
the epidermal barrier [53,54]. The membrane was placed in the diffusion cell sandwiching the donor
and receptor compartments. The receiver solution contained absolute ethanol and the donor chamber
was filled with 1 g of formulation at 2 mg/g of BC (cream, ointment or hydrogel). In this study,
BC was employed as reference compound because of its structural similarity with FX. The whole
diffusion cell was thermostated maintaining the temperature at 32 ◦C. Aliquots of 0.5 mL were
withdrawn from the receptor chamber after 0.5, 1, 1.5, 2 and 3 h and replaced with fresh ethanol.
The concentrations of BC were spectrometrically assayed at 454 nm (UV/vis 1601 Shimadzu, Duisburg,
Germany). The cumulative amounts of permeated drug per unit area in the receiver chamber (µg/cm2)
were plotted as a function of time (h). The slope of the linear portion of the plot was presented as
steady state flux (Jss, µg/cm2/h). From the permeation profiles, the AUC was calculated using the
trapezoidal rule as a quantitative parameter for studying the permeation magnitude [55].
4.7. Animals
Female Swiss CD-1 mice (25–30 g) were purchased from Janvier-Labs (Le Genest St Isle,
France) and female SKH-1 hairless mice (18–20 g) from Charles River Laboratories (Écully, France).
Mice were maintained under standard conditions (temperature of 24–25 ◦C, humidity of 70–75%
and 12 h light-12 h dark cycle) and were allowed free access to a standard diet (Panlab) and
water ad libitum. All studies were performed in accordance with the recommendations of the
European Union regarding animal experimentation (Directive of the European Council 2010/63/EU).
The experiments followed protocols approved by the Animal Ethics Committee of the University of
Seville (Protocol 06/04/2018/042).
4.8. Ex Vivo Permeation Studies from Creams
Once the cream carrier was chosen from the previous study, ex vivo diffusion studies were
performed using excised mice skin as a membrane for evaluating the permeation behaviour of
Mar. Drugs 2018, 16, 378 15 of 22
FX-loaded cream. Moreover, Dex-cream was included because it was used as positive control in
the in vivo hyperplasia study. Swiss CD-1 mice were sacrificed by cervical dislocation and full dorsal
skin was excised. A specific portion of the skin was washed with distilled water and cut for the
permeation assay. The study was carried out following the methodology previously reported [56].
Animal skin was inserted between the donor and receiving compartments and adjusted by means of a
pinch clamp. The receiving chamber was filled with 14.5 mL of degassed ethanol absolute and was
thermostated by means of a water bath circulator and a jacket surrounding the cell, maintaining 32 ◦C
in the skin surface. The receiving medium was continuously stirred to avoid diffusion layer effect.
FX-cream (0.2% w/w), FX control solution in ethanol (0.2% w/w) and Dex-cream (0.2% w/w)
were accurately measured and placed on stratum corneum in the donor compartment and sealed with
parafilm. The same procedure as previously described was followed [56]. Absolute ethanol was used
as solvent in the receiver compartment. The concentrations of Dex were spectrometrically assayed
at 254 nm (UV/vis 1601 Shimadzu). The FX content in the ethanol solutions was analyzed by using
HPLC method. The analysis was performed on a Hitachi Elite Lachron HPLC system equipped with a
L-2130 isocratic pump, a diode array detector L-2455 and a L-2200 autosampler. Separation was carried
out within a chromatographic C18 column (Merck, RP-18 LichroCART® 150 mm × 4 mm, 5 µm).
For drug analysis, the injection volume was 10 µL, and the flow rate and column temperature were
set at 1.0 mL/min and 25 ◦C, respectively. The mobile phase consisted of A (formic acid 0.1%) and B
(acetonitrile). The elution program was: 6 min isocratic at 90% B, followed by a gradient to 100% B at
10 min. Afterwards, the column was re-equilibrated during 5 min at 90% B. The cumulative amount of
drug in receptor chamber for the three formulations (FX-cream, FX control solution and Dex-cream)
was measured as a function of time (t, h). The cumulative amount (%) of drug permeated through the
skin (P%) was determined as per the following equation [57]:
P% =
Cn ·V +∑n−1i=1 Ci ·Vi
M
· 100 (1)
where Cn is the drug concentration of the nth sampling point (mg/mL), Ci is the drug concentration
of the ith sample point (mg/mL), V is the total volume (14.5 mL) of liquid in receiving pool, Vi is the
volume (0.5 mL) of the ith sampling points and M is the mass of drug (FX or Dex) [20].
4.9. TPA-Induced Epidermal Hyperplasia Model and Treatments
Female Swiss CD-1 mice (n = 10 per group) were used to study the effect of FX on TPA-induced
hyperplasia in mice dorsal skin. Briefly, the dorsal hair of animals was removed with an electric clipper
and treated with depilatory cream (Deliplus, Barcelona, Spain) [35]. After 24 h, the animals were
assigned to the different groups: Sham (vehicle: 100 mg of cream with 0.2% of ethanol); TPA control
group; TPA-Cream (vehicle: 100 mg of cream with 0.2% of ethanol); Dex-cream (100 mg of cream per
site, containing 200 µg of Dex dissolved in ethanol at 10 µg/mL); FX-cream formulation (100 mg of
cream per site, containing 200 µg of FX dissolved in ethanol at 10 µg/mL). The creams were applied to
the dorsal skin in an area of 1 cm2 using a syringe, during 2 days before the hyperplasia induction.
Mice were anesthetized with ketamine (100 mg/kg of animal) and diazepam (5 mg/kg of animal)
during treatments and TPA challenge. On day 4, TPA (2 nmol of TPA, dissolved in 20 µL of ethanol)
was topically applied to the same areas on all groups except in sham group. After 1 h, FX-cream,
the Dex-cream or vehicle were administered following the mentioned protocol. This procedure was
replicated during two consecutive days. After 24 h of the last TPA dorsal application (day 7), mice
were sacrificed by cervical dislocation and punch biopsies from the treated dorsal skin were weighed
to evaluate edema, before further processing for histology and biochemical parameters.
4.10. MPO Activity
The measurement of MPO activity was used as a marker of neutrophil infiltration [58]. The tissue
was thawed, weighed and homogenized in 10 volumes of 50 mM-PBS (pH 7.4). Then, the homogenate
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was centrifuged at 20,000× g for 20 min at 4 ◦C and the pellet was again homogenized in 10 volumes
of 50 mM-PBS (pH 6) containing hexadecyl trimethylammonium bromide (0.5%) and 10 mM-EDTA.
This homogenate was subjected to one cycle of freezing/thawing and sonicated. The homogenate
samples (50 µL) were added to 96-well microplate and incubated at 37 ◦C for 3 min with a measurement
mix (o-dianisidine dihydrochloride (0.067%), hexadecyl trimethyl-ammonium bromide (0.5%) and
0.3 mM-H2O2). The changes in absorbance were monitorized at 450 nm with a microplate reader
(Labysystem Multiskan EX, Thermo Scientific, New York, NY, USA). MPO activity unit was defined as
the amount of enzyme present that produced a change in absorbance of 1.0 unit/min at 37 ◦C in the
final reaction volume containing acetate. Results are expressed as units/mg tissue [20].
4.11. Histological Study
The samples were fixed in paraformaldehyde, dehydrated by increasing concentrations of ethanol
and embedded in paraffin. For H&E stains, tissue sections were cut to 7 µm on a rotary microtome
(Leica Microsystems, Wetzlar, Germany), mounted on slides, deparaffinized with xylene, rehydrated
through graded alcohols and stained according to standard protocols. All tissue sections were
examined under an Olympus BH-2 microscope (GMI Inc., Ramsey, MN, USA) for determination
of histopathological changes. Epidermal thickness was measured by using Scientific Imaging Systems
(Biophotonics ImageJ Analysis Software; National Institutes of Health, Rockville, MD, USA).
4.12. Immunohistochemical Analysis
COX-2 expression was measured by immunohistochemical analysis by using a streptavidin-
biotin-peroxidase method [59]. Paraffin-embedded dorsal skin sections (7 µm) were mounted on
slides, deparaffinized with xylene and rehydrated through graded alcohols. These sections were
boiled (10 mM citrate buffer (pH 6.0) for 3 min) for antigen retrieval, followed by cooling at room
temperature for 20 min. Endogenous peroxidase was quenched with 0.3% (v/v) hydrogen peroxide
for 20 min and the sections were washed (PBS, 10 min). To minimize the non-specific adsorption
the sections were incubated in normal horse serum (Vectastain Kit; Vector Laboratories, Burlingame,
CA, USA) for 20 min. Afterwards, slides were incubated with rabbit polyclonal anti-COX-2 antibody
(Cayman Chemical, Ann Arbor, MI, USA) (1:300) overnight at 4 ◦C. Then, the samples were treated
with anti-mouse IgG antibody. After 30 min, the cells were incubated with the streptavidin–peroxidase
complex for 30 min, at room temperature (Vectastain Kit; Vector Laboratories, Burlingame, CA, USA).
The enzymatic activities were developed with 3,3′-diaminobenzidine (DAB), and the sections were
counterstained with hematoxylin. Negative control sections were treated in the same way, omitting
the primary antibody. To examine COX-2 immunoreactivity, the microscope Olympus BX61 was used
(Olympus Optical Co. Ltd., Tokyo, Japan). The quantification of immunohistochemical data was done
by counting the number of immunostained cells as percent of total epidermal cells from 10 microscopic
fields of immunostained tissues per animal.
4.13. UVB Irradiation of HaCaT Keratinocytes
Human keratinocytes were exposed to UVB radiation as previously described [60]. Briefly, the
cells were grown to confluence and were treated with different concentrations of FX (10, 30 and 50 µM)
for 1 h. Then, the medium was removed and a thin layer of PBS was added. Cells were exposed to a
single dose of UVB radiation (50 mJ/cm2) for 1 min. The UVB source was a CL-1000M UV Crosslinker
(UVP, Upland, CA, USA), which was used to deliver an energy spectrum of UVB light (280–315 nm;
peak intensity, 302 nm). After UVB irradiation, the cells were supplied with fresh complete medium
and incubated for 24 h.
4.14. Analysis of Intracellular LDH Activity
The measure of cytosolic enzyme LDH is one of the commonly used methods for assessing loss of
cellular membrane integrity. The assay is based on the conversion of lactate to pyruvate in the presence
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of LDH with the consequence oxidation of NADH as previously described [61]. HaCaT cells were
seeded in 6-well plates (5 × 105 cells/well). After 24 h, cells were treated with FX (10, 30 and 50 µM)
for 1 h and then, were irradiated with UVB. After 24 h, cell-free supernatants and cell lysates were
mixed in a 96-well plate and the absorbance was read by using a microplate reader system (Sinergy HT,
Biotek®, Bad Friedrichshall, Germany). LDH leakage was estimated calculating the LDH activity in
the cell-free medium and LDH activity in lysates ratio. Results were represented as the percentage (%)
of change in activity compared with the control cells.
4.15. Intracellular ROS Scavenging Activity
For quantification of ROS in HaCaT cells, the DCF-DA assay was employed [62]. HaCaT cells
were seeded in nin96-well plates (104 cells/well). Non-irradiated cells were used as negative control.
After 24 h, cells were treated with FX (10, 30 and 50 µM) for 1 h and then, were exposed to UVB. Post
irradiation, cells were incubated with 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) solution
(5 mg/mL) in PBS for 30 min [63]. The fluorescence of the 2′,7′-dichlorofluorescein (DCF) product was
determined using a fluorescence plate reader (Sinergy HT, Biotek®, Bad Friedrichshall, Germany) at
485 nm for excitation and 535 nm for emission.
4.16. Determination of IL-6 Production in UVB-Exposed HaCaT Keratinocytes
HaCaT cells (5 × 105 cells/well) were seeded in 6-well plates. After 24 h, cells were treated with
FX (10, 20 and 50 µM) for 1 h and then, were exposed to UVB. After 24 h, supernatant fluids were
collected and ELISA kit (Diaclone GEN-PROBE, Besançon, France) was employed to quantify IL-6
according to the manufacturer’s protocol. The absorbance at 450 nm was read by a microplate reader
(Labysystem Multiskan EX, Thermo Scientific, New York, NY, USA).
4.17. UVB-Induced Erythema in Hairless Mice
Female SKH-1 hairless mice (n = 8 per group) were used to study the effect of FX on UVB-induced
erythema. Animals were distributed to the different groups: Sham (vehicle: 100 mg of cream with
0.2% of ethanol); UVB (100 mg of cream with 0.2% of ethanol); BC-cream (100 mg of cream per site,
containing 200 µg of BC dissolved in ethanol at 10 µg/µL) as reference control; FX-cream (100 mg
per site, containing 200 µg of FX dissolved in ethanol at 10 µg/µL). The formulations were applied
on the dorsal skin (1 cm2/area) by using a syringe, and starting 2 days before irradiation. On day
3, 30 min after application of the substances, all groups except the sham control were exposed to an
acute UVB dose (360 mJ/cm2) as previously described [22]. Then, 48 h after UVB exposure, mice
were macroscopically evaluated and sacrificed. At this end-point time, a pronounced UVB-induced
cutaneous inflammation was shown [4].
4.18. Dermatoscope Measurements
Dorsal skin was macroscopically examined every day by using a multi-dermatoscope
(Dermatoscope MDS 800, Microcaya, Bilbao, Spain). Corneometer® was used to determinate the
hydration in the stratum corneum through electrical capacitance of the skin surface [64]. A Cutometer®
probe was used as suction method to analyse the real elasticity of skin [65]. In the last step, Mexameter®
was employed to analyse the redness skin by melanin index [66]. Every day, dorsal skin of mice was
assessed twice and finally the results were expressed in arbitrary units (a. u.) or by a melanin index
scale (1-36).
4.19. Western Blot Assay
Frozen dorsal skin tissues from UVB-induced erythema model were randomly selected (6 per
group), weighed and homogenized in ice-cold buffer (50 mM Tris-HCl, pH 7.5, 8 mM MgCl2, 5 mM
ethylene glycol bis (2-aminoethyl ether)-N,N,N′,N′-tetra acetic acid, 0.5 mM EDTA, 0.01 mg/mL
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leupeptin, 0.01 mg/mL pepstatin, 0.01 mg/mL aprotinin, 1 mM phenylmethylsulfonyl fluoride, and
250 mM NaCl). The homogenates were centrifuged (12,000× g, 15 min, 4 ◦C), and the supernatants
were collected and stored at −80 ◦C. To determinate the protein concentration of the homogenates
was used the Bradford colorimetric method [67]. Samples of the supernatants with equal amounts of
protein (25 µg) were separated on 10% acrylamide gel by sodium dodecyl sulfate polyacrylamide gel
electrophoresis. Then, the proteins were electrophoretically transferred onto a nitrocellulose membrane
and incubated with specific primary antibodies: rabbit anti-inducible nitric oxide synthase (iNOS)
(1:1000; Stressgen-Enzo Life Sciences, Farmingdale, NY, USA); rabbit anti-COX-2 (1:3000; Cayman
Chemical®, Ann Arbor, MI, USA); rabbit anti-Nrf2, rabbit anti-HO-1 (1:1000; Cell Signaling, Danvers,
MA, USA) overnight at 4 ◦C. After rinsing, the membranes were incubated with the horseradish
peroxidase-linked (HRP) secondary antibody anti-rabbit (1:1000; Cayman Chemical®, Ann Arbor,
MI, USA) or anti-mouse (1:1000; Dako®, Atlanta, GA, USA) containing blocking solution for 1 h at
room temperature. To prove equal loading, the blots were analyzed for β-actin expression using an
anti-β-actin antibody (1:1000; Sigma Aldrich®, St. Louis, MO, USA). Immunodetection was performed
using an enhanced chemiluminescence light-detecting kit (SuperSignal West Pico Chemiluminescent
Substrate, Pierce, IL, USA). Then, the immunosignals were monitorized by using LAS-3000 Imaging
System (Fujifilm Image Reader, Valhalla, NY, USA) and densitometric data were studied after
normalization to the control (housekeeping gene). The signals were analyzed and quantified with
a Scientific Imaging Systems (Biophotonics ImageJ Analysis Software, National Institute of Mental
Health, Bethesda, MD, USA) and expressed as percentage respect to sham control group [68].
4.20. Statistical Analysis
All values in the figures and text are expressed as arithmetic means ± SEM. Data were evaluated
with GraphPad Prism version 5.00 software (GraphPad Software, Inc., San Diego, CA, USA). In all
cases, the Shapiro-Wilk test was used to verify the normality of the data. The Mann-Whitney U-test
was chosen for non-parametric values. The parametric values groups were analyzed by one-way
analysis of variance (ANOVA) followed by Bonferroni’s Multiple Comparison Test. p values < 0.05
were considered statistically significant.
5. Conclusions
In conclusion, the in vitro anti-inflammatory, antioxidant and protective activity of FX has
been confirmed in human keratinocytes. Furthermore, we have demonstrated for the first time
the anti-inflammatory activity of a topical formulation containing FX in hyperplasic skin, reducing cell
infiltrate and epidermal COX-2 expression, which has a main role in the progression of hyperplasia and
the consequent skin damage. In addition, this carotenoid protects mice against superficial skin damage
induced by UVB through inhibition of inflammatory mediators and promotion of antioxidant responses
through Nrf2 pathway. For these reasons, FX, administered in a well-tolerated topical formulation
and that improves its permeation, could be a novel natural adjuvant for preventing exacerbations
associated with skin inflammatory pathologies as well as protecting skin against UV radiation.
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BC β-carotene
COX-2 cyclooxygenase-2
DCF 2′,7′-dichlorofluorescein
DCF-DA dichlorofluorescein diacetate
DCFH-DA 2′,7′-dichlorodihydrofluorescein diacetate
Dex dexamethasone
FX fucoxanthin
H&E hematoxylin and eosin
HO-1 heme oxygenase-1
IL interleukin
LDH lactate dehydrogenase
LPS lipopolysaccharide
MPO myeloperoxidase
Nrf2 nuclear factor E2-related factor 2
ROS reactive oxygen species
SRB sulforhodamine B
TNF-α tumor necrosis factor alpha
TPA 12-O-tetradecanoylphorbol-13-acetate
UV ultraviolet
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